

## **Fulcrum Therapeutics to Present at the 10th Annual BioPharm America International Partnering Conference**

September 25, 2017 at 8:00 AM EDT

Cambridge, Mass., Sept. 25, 2017 – [Fulcrum Therapeutics](#), a company focused on discovering and developing small molecule therapies that unlock gene regulation to treat serious genetic diseases, will present at the 10th Annual BioPharm America International Partnering Conference in Boston, Mass.

Robert Gould, Ph.D., Fulcrum's President and Chief Executive Officer, will give a presentation in the Rare and Orphan Disease category titled "Restoring Balance in Gene Regulation" at the Sheraton Boston Hotel on September 27th at 10:45am.

### **About Fulcrum Therapeutics**

Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients and their families by transforming gene regulation in disease. Fulcrum's therapies are based on modulating gene regulation via control of genetic on and off switches of disease genes. Fulcrum, headquartered in Cambridge, Mass., was launched by Third Rock Ventures in 2016 and named a "Fierce 15" company later that year. For more information, please visit [www.fulcrumtx.com](http://www.fulcrumtx.com).

### **CONTACTS:**

Media:  
Sarah Sutton  
Ten Bridge Communications  
[sarah@tenbridgecommunications.com](mailto:sarah@tenbridgecommunications.com)  
518-932-3680